ArticleEuropean journal of medical research2025
Plasma lipidomic analysis reveals distinct lipid alterations in patients with pulmonary tuberculosis.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Mapping of Lipidome Profile in Drug-Resistant Clinical Isolates ofLife (Basel, Switzerland) · 2026Article
- Role of Lipidomics in Respiratory Tract Infections: A Systematic Review of Emerging Evidence.Microorganisms · 2025Review
- Lipidomics-Based Identification of Plasma Lipid Biomarkers in Tuberculosis-Coronary Artery Disease Comorbidity.Infection and drug resistance · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectiveThis study aimed to characterize the plasma lipidomic profile of patients with pulmonary tuberculosis (PTB), identify lipid species with potential diagnostic utility, and explore their associations with clinical parameters to inform future biomarker development and mechanistic understanding.
methodsIn a case-control study, 50 newly diagnosed PTB patients and 50 age- and sex-matched healthy controls (HC) were enrolled between April and June 2021. Plasma samples were analyzed using LC-MS/MS-based lipidomics. Multivariate modeling and univariate statistical analyses were performed to identify differential lipid species. Receiver-operating characteristic (ROC) curves evaluated diagnostic performance, and correlation analyses assessed associations with clinical indicators.
resultsA total of 633 lipid species were profiled, with 61 showing significant differential expression between PTB and HC groups. When compared with controls, PTB patients exhibited significantly lower plasma levels of total cholesterol, triglycerides, HDL, and LDL (all P < 0.05), as well as reduced triacylglycerol (TAG), ceramide (CER), and hexosylceramide (HCER). In contrast, phosphatidylethanolamine (PE) and phosphatidylcholine (PC) levels were elevated in PTB. ROC analysis identified several lipid species-particularly CER(24:0) H, HCER(d18:0/22:0) H, and PE(18:1/18:1)-with strong discriminative power (AUC > 0.75). Correlation analysis revealed weak-to-moderate associations of select lipids with age and glucose, but minimal or no correlation with BMI, sex, or smoking, indicating that lipidomic alterations are primarily disease-driven.
conclusionPTB patients display a distinct plasma lipidomic signature, marked by disrupted glycerolipid and sphingolipid metabolism. These findings support the diagnostic value of lipidomic profiling and provide insights into PTB-associated metabolic disturbances, laying a foundation for future biomarker validation and therapeutic exploration.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.